Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

NCT01421472 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT01421472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01421472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2011
Completion date
June 30, 2014
Enrollment
196 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

er positive, her2 negative breast cancer patients, triple negative breast cancer patients